J. Smolen, J. Braun, M. Dougados, P. Emery, O. FitzGerald, P. Helliwell, A. Kavanaugh, T. Kvien, R. Landewé, T. Luger, P. Mease, I. Olivieri, J. Reveille, C. Ritchlin, M. Rudwaleit, M. Schoels, J. Sieper, M. Wit, X. Baraliakos, N. Betteridge, R. Burgos-Vargas, E. Collantes-Estévez, A. Deodhar, D. Elewaut, L. Gossec, Merryn Jongkees, M. Maccarone, K. Redlich, F. Bosch, J. Wei, K. Winthrop, D. Heijde (2013)
Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task forceAnnals of the Rheumatic Diseases, 73
L. Coates, N. Navarro-Coy, S. Brown, S. Brown, L. McParland, H. Collier, E. Skinner, J. Law, A. Moverley, S. Pavitt, C. Hulme, P. Emery, P. Conaghan, P. Helliwell (2013)
The TICOPA protocol (TIght COntrol of Psoriatic Arthritis): a randomised controlled trial to compare intensive management versus standard care in early psoriatic arthritisBMC Musculoskeletal Disorders, 14
L. Gossec, M. Wit, U. Kiltz, J. Braun, U. Kalyoncu, R. Scrivo, M. Maccarone, L. Carton, K. Otsa, Imre Sooäär, T. Heiberg, H. Bertheussen, J. Cañete, A. Lombarte, A. Balanescu, Alina Dinte, K. Vlam, J. Smolen, T. Stamm, D. Niedermayer, G. Békés, D. Veale, P. Helliwell, Andrew Parkinson, T. Luger, T. Kvien (2014)
A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiativeAnnals of the Rheumatic Diseases, 73
L. Coates, A. Moverley, L. McParland, Sarah Brown, N. Navarro-Coy, J. O’Dwyer, D. Meads, P. Emery, P. Conaghan, P. Helliwell (2014)
Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trialThe Lancet, 386
J. Brockbank, M. Stein, C. Schentag, D. Gladman (2004)
Dactylitis in psoriatic arthritis: a marker for disease severity?Annals of the Rheumatic Diseases, 64
The Oxford Levels of Evidence
O. FitzGerald, M. Haroon, J. Giles, R. Winchester (2015)
Concepts of pathogenesis in psoriatic arthritis: genotype determines clinical phenotypeArthritis Research & Therapy, 17
D. Gladman, R. Landewé, N. McHugh, O. FitzGerald, D. Thaçi, L. Coates, P. Mease, A. Qureshi, G. Krueger, C. Ritchlin, A. Kavanaugh, A. Garg (2010)
Composite Measures in Psoriatic Arthritis: GRAPPA 2008The Journal of Rheumatology, 37
L. Gossec, J. Smolen, C. Gaujoux-Viala, Z. Ash, H. Marzo-Ortega, D. Heijde, O. FitzGerald, D. Aletaha, P. Bálint, D. Boumpas, Jürgen Braun, F. Breedveld, G. Burmester, J. Cañete, M. Wit, H. Dagfinrud, K. Vlam, M. Dougados, P. Helliwell, A. Kavanaugh, T. Kvien, R. Landewé, T. Luger, M. Maccarone, D. McGonagle, N. McHugh, I. McInnes, C. Ritchlin, J. Sieper, P. Tak, G. Valesini, J. Vencovský, K. Winthrop, A. Zink, P. Emery (2011)
European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapiesAnnals of the Rheumatic Diseases, 71
藤井隆夫 (2016)
Treating rheumatoid arthritis to the target―関節リウマチの治療戦略をここまで変えたものは何か―
D. Heijde, D. Aletaha, L. Carmona, C. Edwards, T. Kvien, M. Kouloumas, P. Machado, S. Oliver, M. Wit, M. Dougados (2014)
2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendationsAnnals of the Rheumatic Diseases, 74
T. Kopp, E. Riedl, C. Bangert, E. Bowman, E. Greisenegger, A. Horowitz, H. Kittler, W. Blumenschein, T. Mcclanahan, T. Marbury, C. Zachariae, Danlin Xu, Xiaoli Hou, A. Mehta, A. Zandvliet, D. Montgomery, F. Aarle, Sauzanne Khalilieh (2015)
Clinical improvement in psoriasis with specific targeting of interleukin-23Nature, 521
V. Strand, G. Schett, ChiaChi Hu, R. Stevens (2013)
Patient-reported Health-related Quality of Life with Apremilast for Psoriatic Arthritis: A Phase II, Randomized, Controlled StudyThe Journal of Rheumatology, 40
F. Cantini, L. Niccoli, C. Nannini, E. Cassarà, P. Pasquetti, I. Olivieri, C. Salvarani (2009)
Criteria, Frequency, and Duration of Clinical Remission in Psoriatic Arthritis Patients with Peripheral Involvement Requiring Second-line DrugsThe Journal of Rheumatology, 83
M. Schoels, D. Aletaha, Julia Funovits, A. Kavanaugh, D. Baker, J. Smolen (2010)
Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritisAnnals of the Rheumatic Diseases, 69
V. Nell-Duxneuner, T. Stamm, K. Machold, S. Pflugbeil, D. Aletaha, J. Smolen (2009)
Evaluation of the appropriateness of composite disease activity measures for assessment of psoriatic arthritisAnnals of the Rheumatic Diseases, 69
S. Haque (2011)
Ethics approval This study was conducted with the approval of the East London and City Health Authority Ethic Committee. Provenance and peer review Not commissioned; externally peer reviewed.
I. Janţă, L. Martínez-Estupiñán, L. Valor, M. Montoro, O. Rodriguez, I. Aragüés, N. Bello, D. Hernández-Flórez, M. Hinojosa, J. Martínez-Barrio, J. Nieto‐González, J. Ovalles-Bonilla, Carlos González, F. López-longo, I. Monteagudo, E. Naredo, L. Carreño (2015)
Comparison between full and tapered dosages of biologic therapies in psoriatic arthritis patients: clinical and ultrasound assessmentClinical Rheumatology, 34
A. Orbai, J. Weitz, E. Siegel, S. Siebert, L. Savage, S. Aydın, J. Luime, O. Elkayam, Barbara Neerinckx, S. Urbanček, K. Vlam, C. Ritchlin (2014)
Systematic Review of Treatment Effectiveness and Outcome Measures for Enthesitis in Psoriatic ArthritisThe Journal of Rheumatology, 41
A. Haddad, A. Thavaneswaran, I. Ruiz-Arruza, F. Pellett, V. Chandran, R. Cook, D. Gladman (2015)
Minimal Disease Activity and Anti–Tumor Necrosis Factor Therapy in Psoriatic ArthritisArthritis Care & Research, 67
Rheumatology B Department
(2010)
Leiden, the Netherlands
Institute and Clinic of
E. Lie, D. Heijde, T. Uhlig, M. Heiberg, W. Koldingsnes, E. Rødevand, C. Kaufmann, K. Mikkelsen, T. Kvien (2009)
Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritisAnnals of the Rheumatic Diseases, 69
D. Heijde, J. Sieper, W. Maksymowych, M. Dougados, R. Burgos-Vargas, R. Landewé, M. Rudwaleit, J. Braun (2011)
2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritisAnnals of the Rheumatic Diseases, 70
P. Simon, C. Pfoehler, R. Bergner, M. Schreiber, Michael Pfreundschuh, Gunter Assmann (2012)
Swollen joint count in psoriatic arthritis is associated with progressive radiological damage in hands and feet.Clinical and experimental rheumatology, 30 1
W. Tillett, L. Eder, N. Goel, M. Wit, D. Gladman, O. FitzGerald, Willemina Campbell, P. Helliwell, L. Gossec, A. Orbai, A. Ogdie, V. Strand, N. McHugh, P. Mease (2015)
Enhanced Patient Involvement and the Need to Revise the Core Set — Report from the Psoriatic Arthritis Working Group at OMERACT 2014The Journal of Rheumatology, 42
P. Healy, P. Helliwell (2008)
Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis.Arthritis and rheumatism, 59 5
B. Glintborg, M. Østergaard, L. Dreyer, N. Krogh, U. Tarp, M. Hansen, S. Rifbjerg-Madsen, T. Lorenzen, M. Hetland (2011)
Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor α therapy: results from the nationwide Danish DANBIO registry.Arthritis and rheumatism, 63 2
G. Guyatt, A. Oxman, R. Kunz, Roman Jaeschke, M. Helfand, A. Liberati, G. Vist, H. Schünemann (2008)
Incorporating considerations of resources use into grading recommendationsBMJ : British Medical Journal, 336
Jochen Schmitt, S. Rosumeck, G. Thomaschewski, B. Sporbeck, E. Haufe, A. Nast (2014)
Efficacy and safety of systemic treatments for moderate‐to‐severe psoriasis: meta‐analysis of randomized controlled trialsBritish Journal of Dermatology, 170
(2016)
Section on RheumatologyPediatric Clinical Practice Guidelines & Policies
P. Helliwell, O. FitzGerald, J. Fransen, D. Gladman, Gerald Kreuger, K. Callis-Duffin, N. McHugh, P. Mease, V. Strand, R. Waxman, V. Azevedo, A. ostos, S. Carneiro, A. Cauli, L. Espinoza, J. Flynn, N. Hassan, P. Healy, E. Kerzberg, Y. Lee, E. Lubrano, A. Marchesoni, H. Marzo-Ortega, G. Porru, Elvia Moreta, P. Nash, H. Raffayova, R. Ranza, S. Raychaudhuri, E. Roussou, R. Scarpa, Y. Song, E. Soriano, P. Tak, I. Újfalussy, K. Vlam, J. Walsh (2012)
The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project)Annals of the Rheumatic Diseases, 72
Medicine Faculty, Paris Descartes University, Paris, France
B. Michelsen, R. Fiane, A. Diamantopoulos, D. Soldal, I. Hansen, T. Sokka, A. Kavanaugh, G. Haugeberg (2015)
A Comparison of Disease Burden in Rheumatoid Arthritis, Psoriatic Arthritis and Axial SpondyloarthritisPLoS ONE, 10
D. Baeten, X. Baraliakos, J. Braun, J. Sieper, P. Emery, D. Heijde, I. McInnes, J. Laar, R. Landewé, P. Wordsworth, J. Wollenhaupt, H. Kellner, J. Paramarta, Jiawei Wei, A. Brachat, S. Bek, D. Laurent, Yali Li, Ying Wang, A. Bertolino, S. Gsteiger, A. Wright, W. Hueber (2013)
Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trialThe Lancet, 382
F. Cantini, L. Niccoli, E. Cassarà, O. Kaloudi, C. Nannini (2012)
Sustained maintenance of clinical remission after adalimumab dose reduction in patients with early psoriatic arthritis: a long-term follow-up studyBiologics : Targets & Therapy, 6
H. Sofen, Stacy Smith, R. Matheson, C. Leonardi, C. Calderon, C. Brodmerkel, Katherine Li, K. Campbell, S. Marciniak, Y. Wasfi, Yuhua Wang, P. Szapary, J. Krueger (2014)
Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis.The Journal of allergy and clinical immunology, 133 4
F. Siannis, V. Farewell, R. Cook, C. Schentag, D. Gladman (2005)
Clinical and radiological damage in psoriatic arthritisAnnals of the Rheumatic Diseases, 65
B. Kirkham, K. Vlam, Wenzhi Li, R. Boggs, L. Mallbris, H. Nab, M. Tarallo (2015)
Early treatment of psoriatic arthritis is associated with improved patient-reported outcomes: findings from the etanercept PRESTA trial.Clinical and experimental rheumatology, 33 1
G. Schett, J. Wollenhaupt, K. Papp, R. Joos, J. Rodrigues, A. Vessey, ChiaChi Hu, R. Stevens, K. Vlam (2012)
Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study.Arthritis and rheumatism, 64 10
F. Cantini, L. Niccoli, C. Nannini, E. Cassarà, P. Pasquetti, I. Olivieri, C. Salvarani (2008)
Frequency and duration of clinical remission in patients with peripheral psoriatic arthritis requiring second-line drugs.Rheumatology, 47 6
D. Gladman, P. Mease, E. Choy, C. Ritchlin, R. Perdok, E. Sasso
Open Access Research Article Risk Factors for Radiographic Progression in Psoriatic Arthritis: Subanalysis of the Randomized Controlled Trial Adept
P. Mease (2013)
Is reduction or discontinuation of therapy an acceptable possibility in psoriatic arthritis?Clinical and experimental rheumatology, 31 4 Suppl 78
H. Duncan, D. OberG, W. Eyler (1965)
PSORIATIC ARTHRITIS.Henry Ford Hospital medical bulletin, 13
Infl iximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study
In patients with active enthesitis and/or dactylitis and insufficient response to NSAIDs or local glucocorticoid injections, therapy with a bDMARD should be considered, which
U. Lindqvist, G. Alenius, T. Husmark, E. Theander, G. Holmström, P. Larsson (2008)
The Swedish early psoriatic arthritis register-- 2-year followup: a comparison with early rheumatoid arthritis.The Journal of rheumatology, 35 4
M. Chimenti, M. Esposito, A. Giunta, D. Graceffa, G. Babino, M. Teoli, A. Mazzotta, R. Perricone, S. Chimenti (2013)
Remission of Psoriatic Arthritis after Etanercept Discontinuation: Analysis of Patients' Clinical Characteristics Leading to Disease RelapseInternational Journal of Immunopathology and Pharmacology, 26
L. Coates, P. Helliwell (2010)
Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial dataArthritis Care & Research, 62
A. Kavanaugh, A. Menter, A. Mendelsohn, Yaung-Kaung Shen, Seina Lee, A. Gottlieb (2010)
Effect of ustekinumab on physical function and health-related quality of life in patients with psoriatic arthritis: a randomized, placebo-controlled, phase II trialCurrent Medical Research and Opinion, 26
Centre for Arthritis and Rheumatic Disease, Dublin Academic Medical Centre, St. Vincent ’ s University Hospital, Dublin, Ireland
G. Kingsley, A. Kowalczyk, H. Taylor, F. Ibrahim, J. Packham, N. McHugh, D. Mulherin, G. Kitas, K. Chakravarty, B. Tom, A. O’Keeffe, P. Maddison, D. Scott (2012)
A randomized placebo-controlled trial of methotrexate in psoriatic arthritisRheumatology (Oxford, England), 51
M. Haroon, P. Gallagher, O. FitzGerald (2015)
Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis.Annals of the rheumatic diseases, 74 6
J. Hoes, J. Jacobs, S. Verstappen, J. Bijlsma, G. Heijden (2008)
Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysisAnnals of the Rheumatic Diseases, 68
E. Araujo, S. Finzel, M. Englbrecht, D. Schreiber, F. Faustini, A. Hueber, K. Nas, J. Rech, G. Schett (2013)
High incidence of disease recurrence after discontinuation of disease-modifying antirheumatic drug treatment in patients with psoriatic arthritis in remissionAnnals of the Rheumatic Diseases, 74
Schoen
D. Jadon, G. Shaddick, W. Tillett, E. Korendowych, G. Robinson, N. Waldron, C. Cavill, N. McHugh (2015)
Psoriatic Arthritis Mutilans: Characteristics and Natural Radiographic HistoryThe Journal of Rheumatology, 42
M. Schoels, D. Aletaha, F. Alasti, J. Smolen (2015)
Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA scoreAnnals of the Rheumatic Diseases, 75
I. McInnes, A. Kavanaugh, A. Gottlieb, L. Puig, P. Rahman, C. Ritchlin, C. Brodmerkel, Shu Li, Yuhua Wang, A. Mendelsohn, M. Doyle (2013)
Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trialThe Lancet, 382
E. Siegel, A. Orbai, C. Ritchlin (2015)
Targeting extra-articular manifestations in PsA: a closer look at enthesitis and dactylitisCurrent Opinion in Rheumatology, 27
W. Park, P. Hrycaj, S. Jeka, V. Kovalenko, G. Lysenko, P. Miranda, H. Mikažāne, S. Gutiérrez-Ureña, M. Lim, Yeon-Ah Lee, Sang Lee, Houng Kim, D. Yoo, J. Braun (2013)
A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS studyAnnals of the Rheumatic Diseases, 72
Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Potenza, Italy
C. Palazzi, S. d'Angelo, P. Leccese, A. Padula, I. Olivieri (2014)
Safety of anti-tumor necrosis factor agents in psoriatic arthritis – an updateExpert Opinion on Drug Safety, 13
OCEBM Levels of Evidence Working Group
J. Smolen, F. Breedveld, G. Burmester, V. Bykerk, M. Dougados, P. Emery, T. Kvien, M. Navarro-Compán, S. Oliver, M. Schoels, M. Scholte-Voshaar, T. Stamm, M. Stoffer, T. Takeuchi, D. Aletaha, J. Andreu, M. Aringer, Martin Bergman, N. Betteridge, H. Bijlsma, H. Burkhardt, M. Cardiel, B. Combe, P. Durez, J. Fonseca, A. Gibofsky, J. Gómez-Reino, W. Graninger, P. Hannonen, B. Haraoui, M. Kouloumas, R. Landewé, E. Martı́n-Mola, P. Nash, M. Ostergaard, A. Östör, P. Richards, T. Sokka-Isler, C. Thorne, A. Tzioufas, R. Vollenhoven, M. Wit, D. Heijde (2015)
Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task forceAnnals of the Rheumatic Diseases, 75
K. Fagerli, E. Lie, D. Heijde, M. Heiberg, Å. Lexberg, E. Rødevand, S. Kalstad, K. Mikkelsen, T. Kvien (2013)
The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD studyAnnals of the Rheumatic Diseases, 73
D. Felson, J. Smolen, G. Wells, Bin Zhang, L. Tuyl, Julia Funovits, D. Aletaha, C. Allaart, J. Bathon, S. Bombardieri, P. Brooks, A. Brown, M. Matucci-Cerinic, Hyon Choi, B. Combe, M. Wit, M. Dougados, P. Emery, D. Furst, J. Gómez-Reino, G. Hawker, E. Keystone, D. Khanna, J. Kirwan, T. Kvien, R. Landewé, J. Listing, K. Michaud, E. Martı́n-Mola, P. Montie, T. Pincus, P. Richards, J. Siegel, L. Simon, T. Sokka, V. Strand, P. Tugwell, A. Tyndall, D. Heijde, S. Verstappen, B. White, F. Wolfe, A. Zink, M. Boers (2011)
American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical TrialsAnnals of the Rheumatic Diseases, 70
Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
J. Weinberg (2010)
Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trialYearbook of Dermatology and Dermatologic Surgery, 2010
A. Armstrong, J. Gelfand, A. Garg (2014)
Outcomes Research in Psoriasis and Psoriatic Arthritis Using Large Databases and Research Networks: A Report from the GRAPPA 2013 Annual MeetingThe Journal of Rheumatology, 41
Vibeke Strand
Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment
P. Helliwell, O. FitzGerald, J. Fransen (2014)
Composite Disease Activity and Responder Indices for Psoriatic Arthritis: A Report from the GRAPPA 2013 Meeting on Development of Cutoffs for Both Disease Activity States and ResponseThe Journal of Rheumatology, 41
L Eder, A Thavaneswaran, V Chandran (2014)
Tumour necrosis factor α blockers are more effective than methotrexate in the inhibition of radiographic joint damage progression among patients with psoriatic arthritis, 73
E. Theander, T. Husmark, G. Alenius, P. Larsson, A. Teleman, M. Geijer, U. Lindqvist (2013)
Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA)Annals of the Rheumatic Diseases, 73
L. Cresswell, V. Chandran, V. Farewell, D. Gladman (2010)
Inflammation in an individual joint predicts damage to that joint in psoriatic arthritisAnnals of the Rheumatic Diseases, 70
G. Guyatt, A. Oxman, R. Kunz, Y. Falck-Ytter, G. Vist, A. Liberati, H. Schünemann (2008)
Going from evidence to recommendationsBMJ : British Medical Journal, 336
P. Mease, M. Heckaman, S. Kary, H. Kupper (2013)
Application and Modifications of Minimal Disease Activity Measures for Patients with Psoriatic Arthritis Treated with Adalimumab: Subanalyses of ADEPTThe Journal of Rheumatology, 40
P. Helliwell, W. Taylor (2008)
Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs -- comparison of drugs and adverse reactions.The Journal of rheumatology, 35 3
Shawn Rose, S. Toloza, W. Bautista-Molano, P. Helliwell (2014)
Comprehensive Treatment of Dactylitis in Psoriatic ArthritisThe Journal of Rheumatology, 41
M. Stoffer, M. Schoels, J. Smolen, D. Aletaha, F. Breedveld, G. Burmester, V. Bykerk, M. Dougados, P. Emery, B. Haraoui, J. Gómez-Reino, T. Kvien, P. Nash, V. Navarro-Compán, M. Scholte-Voshaar, R. Vollenhoven, D. Heijde, T. Stamm (2015)
Evidence for treating rheumatoid arthritis to target: results of a systematic literature search updateAnnals of the Rheumatic Diseases, 75
D. Gladman, V. Farewell, C. Nadeau (1995)
Clinical indicators of progression in psoriatic arthritis: multivariate relative risk model.The Journal of rheumatology, 22 4
Department of Rheumatology, St. Vincent ’ s University Hospital and Conway Institute, University College Dublin, Dublin, Ireland
Z. Ash, C. Gaujoux-Viala, L. Gossec, E. Hensor, O. FitzGerald, K. Winthrop, D. Heijde, P. Emery, J. Smolen, H. Marzo-Ortega (2011)
A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritisAnnals of the Rheumatic Diseases, 71
B. Leeb, I. Andel, J. Sautner, Christian Fassl, T. Nothnagl, B. Rintelen (2007)
The Disease Activity Score in 28 joints in rheumatoid arthritis and psoriatic arthritis patients.Arthritis and rheumatism, 57 2
F. Bosch, A. Kavanaugh, M. Kron, H. Kupper, P. Mease (2015)
Clinical Remission in Patients with Active Psoriatic Arthritis Treated with Adalimumab and Correlations in Joint and Skin ManifestationsThe Journal of Rheumatology, 42
Division of Rheumatology, University Hospitals Leuven, Leuven, Belgium
J. Paccou, D. Wendling (2015)
Current treatment of psoriatic arthritis: update based on a systematic literature review to establish French Society for Rheumatology (SFR) recommendations for managing spondyloarthritis.Joint, bone, spine : revue du rhumatisme, 82 2
DD Gladman, PJ Mease, EHS Choy (2010)
Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT, 12
N. McHugh, C. Balachrishnan, S. Jones (2003)
Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study.Rheumatology, 42 6
Institute of Infection, Immunity and In fl ammation,
D. Gladman, A. Thavaneswaran, V. Chandran, R. Cook (2011)
Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease?Annals of the Rheumatic Diseases, 70
A. Kavanaugh, C. Ritchlin, P. Rahman, L. Puig, A. Gottlieb, Shu Li, Yuhua Wang, L. Noonan, C. Brodmerkel, Michael Song, A. Mendelsohn, I. McInnes (2014)
Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trialsAnnals of the Rheumatic Diseases, 73
L. Eder, V. Chandran, J. Ueng, S. Bhella, Ker-Ai Lee, P. Rahman, A. Pope, R. Cook, D. Gladman (2010)
Predictors of response to intra-articular steroid injection in psoriatic arthritis.Rheumatology, 49 7
M. Schoels, J. Braun, M. Dougados, P. Emery, O. FitzGerald, A. Kavanaugh, T. Kvien, R. Landewé, T. Luger, P. Mease, I. Olivieri, J. Reveille, C. Ritchlin, M. Rudwaleit, J. Sieper, J. Smolen, M. Wit, D. Heijde (2013)
Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritisAnnals of the Rheumatic Diseases, 73
D. Gladman, V. Chandran (2011)
Review of Clinical Registries of Psoriatic Arthritis: Lessons Learned? Value for the Future?Current Rheumatology Reports, 13
L. Coates, J. Fransen, P. Helliwell (2009)
Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatmentAnnals of the Rheumatic Diseases, 69
P. Helliwell, Laura Coates (2015)
Interleukin-17 inhibition in psoriatic arthritisThe Lancet, 386
I. McInnes, P. Mease, B. Kirkham, A. Kavanaugh, C. Ritchlin, P. Rahman, D. Heijde, R. Landewé, P. Conaghan, A. Gottlieb, H. Richards, L. Pricop, G. Ligozio, M. Patekar, S. Mpofu (2015)
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet, 386
S. Iervolino, M. Minno, R. Peluso, M. Lofrano, A. Russolillo, G. Minno, R. Scarpa (2012)
Predictors of Early Minimal Disease Activity in Patients with Psoriatic Arthritis Treated with Tumor Necrosis Factor-α BlockersThe Journal of Rheumatology, 39
A. Kavanaugh, P. Mease, J. Gómez-Reino, A. Adebajo, J. Wollenhaupt, D. Gladman, E. Lespessailles, S. Hall, M. Hochfeld, ChiaChi Hu, D. Hough, R. Stevens, G. Schett (2014)
Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitorAnnals of the Rheumatic Diseases, 73
F. Salaffi, A. Ciapetti, M. Carotti, S. Gasparini, M. Gutierrez (2014)
Disease Activity in Psoriatic Arthritis: Comparison of the Discriminative Capacity and Construct Validity of Six Composite Indices in a Real WorldBioMed Research International, 2014
Christopher Ritchlin, Proton Rahman, A. Kavanaugh, Iain McInnes, Lluís Puig, Shu Li, Yuhua Wang, Yaung-Kaung Shen, M. Doyle, A. Mendelsohn, Alice Gottlieb (2014)
Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled,Annals of the Rheumatic Diseases, 73
C. Gaujoux-Viala, L. Gossec (2014)
When and for how long should glucocorticoids be used in rheumatoid arthritis? International guidelines and recommendationsAnnals of the New York Academy of Sciences, 1318
D. Felson, J. Smolen, G. Wells, Bin Zhang, L. Tuyl, Julia Funovits, D. Aletaha, C. Allaart, J. Bathon, S. Bombardieri, P. Brooks, A. Brown, M. Matucci-Cerinic, Hyon Choi, B. Combe, M. Wit, M. Dougados, P. Emery, D. Furst, J. Gómez-Reino, G. Hawker, E. Keystone, D. Khanna, J. Kirwan, T. Kvien, R. Landewé, J. Listing, K. Michaud, E. Martı́n-Mola, P. Montie, T. Pincus, P. Richards, J. Siegel, L. Simon, T. Sokka, V. Strand, P. Tugwell, A. Tyndall, D. Heijde, S. Verstappen, B. White, F. Wolfe, A. Zink, M. Boers (2011)
American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials.Arthritis and rheumatism, 63 3
S. Ramiro, J. Smolen, R. Landewé, D. Heijde, M. Dougados, P. Emery, M. Wit, M. Cutolo, S. Oliver, L. Gossec (2015)
Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritisAnnals of the Rheumatic Diseases, 75
Section of Musculoskeletal Disease
A. Moverley, L. Coates, H. Marzo-Ortega, R. Waxman, D. Torgerson, K. Cocks, J. Watson, P. Helliwell (2015)
A feasibility study for a randomised controlled trial of treatment withdrawal in psoriatic arthritis (REmoval of treatment for patients in REmission in psoriatic ArThritis (RETREAT (F))Clinical Rheumatology, 34
Alexander Fraser, A. Kuijk, R. Westhovens, Z. Karim, R. Wakefield, A. Gerards, R. Landewé, S. Steinfeld, P. Emery, B. Dijkmans, D. Veale (2004)
A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritisAnnals of the Rheumatic Diseases, 64
J. Curtis, T. Beukelman, A. Onofrei, S. Cassell, J. Greenberg, A. Kavanaugh, G. Reed, V. Strand, J. Kremer (2009)
Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomideAnnals of the Rheumatic Diseases, 69
A. Mumtaz, P. Gallagher, B. Kirby, R. Waxman, L. Coates, Douglas J, P. Helliwell, O. FitzGerald (2010)
Development of a preliminary composite disease activity index in psoriatic arthritisAnnals of the Rheumatic Diseases, 70
L. Coates, R. Cook, Ker-Ai Lee, V. Chandran, D. Gladman (2010)
Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohortArthritis Care & Research, 62
R. Wang (2016)
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trialYearbook of Medicine
C. Ritchlin, A. Kavanaugh, D. Gladman, P. Mease, P. Helliwell, W. Boehncke, K. Vlam, D. Fiorentino, O. FitzGerald, A. Gottlieb, N. McHugh, P. Nash, A. Qureshi, E. Soriano, W. Taylor (2008)
Treatment recommendations for psoriatic arthritisAnnals of the Rheumatic Diseases, 68
P. Mease, M. Genovese, M. Greenwald, C. Ritchlin, A. Beaulieu, A. Deodhar, R. Newmark, J. Feng, N. Erondu, A. Nirula (2014)
Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis.The New England journal of medicine, 370 24
Lars Kristensen, A. Gülfe, T. Saxne, P. Geborek (2007)
Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group registerAnnals of the Rheumatic Diseases, 67
M. Minno, P. Ambrosino, R. Lupoli, A. Minno, M. Tasso, R. Peluso, E. Tremoli (2015)
Cardiovascular risk markers in patients with psoriatic arthritis: A meta-analysis of literature studiesAnnals of Medicine, 47
I. McInnes, J. Sieper, J. Braun, P. Emery, D. Heijde, J. Isaacs, G. Dahmen, J. Wollenhaupt, H. Schulze-Koops, Joseph Kogan, Shengling Ma, Martin Schumacher, A. Bertolino, W. Hueber, P. Tak (2013)
Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trialAnnals of the Rheumatic Diseases, 73
A. Ogdie, S. Schwartzman, M. Husni (2015)
Recognizing and managing comorbidities in psoriatic arthritisCurrent Opinion in Rheumatology, 27
P. Machado, S. Raychaudhuri (2014)
Disease activity measurements and monitoring in psoriatic arthritis and axial spondyloarthritis.Best practice & research. Clinical rheumatology, 28 5
S. Bond, V. Farewell, C. Schentag, D. Gladman (2006)
Predictors for radiological damage in psoriatic arthritis: results from a single centreAnnals of the Rheumatic Diseases, 66
L. Coates, C. Ritchlin, A. Kavanaugh (2014)
GRAPPA Treatment Recommendations: An Update from the GRAPPA 2013 Annual MeetingThe Journal of Rheumatology, 41
J. Smolen, D. Heijde, K. Machold, D. Aletaha, R. Landewé (2013)
Proposal for a new nomenclature of disease-modifying antirheumatic drugsAnnals of the Rheumatic Diseases, 73
Sweden and School of Business, Engineering and Science
W. Tillett, D. Jadon, G. Shaddick, C. Cavill, E. Korendowych, C. Vries, N. McHugh (2013)
Smoking and delay to diagnosis are associated with poorer functional outcome in psoriatic arthritisAnnals of the Rheumatic Diseases, 72
Annals of the Rheumatic Diseases – Unpaywall
Published: Dec 7, 2015
Access the full text.
Sign up today, get DeepDyve free for 14 days.